Mankind Pharma Ltd

Mankind Pharma Ltd

₹ 2,116 -1.53%
16 Jul - close price
About

Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.[1]

Key Points

Leadership[1]

<h1>1 Rank in Prescriptions over the last 5 yrs.</h1> <h1>Youngest in Top 5 of the IPM</h1> <h1>4 By value in the IPM</h1> <h1>4 Consumer Healthcare brands Market ranked #1 in their categories</h1>
  • Market Cap 84,762 Cr.
  • Current Price 2,116
  • High / Low 2,490 / 1,680
  • Stock P/E 46.5
  • Book Value 240
  • Dividend Yield 0.00 %
  • ROCE 26.1 %
  • ROE 21.0 %
  • Face Value 1.00

Pros

  • Company is almost debt free.
  • Company has delivered good profit growth of 28.8% CAGR over last 5 years

Cons

  • Stock is trading at 8.81 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Working capital days have increased from 74.3 days to 124 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
1,645 2,061 2,258 1,936 1,872 2,300 2,453 2,359 2,153
1,336 1,641 1,735 1,563 1,491 1,761 1,818 1,755 1,605
Operating Profit 309 420 522 374 381 539 635 603 547
OPM % 19% 20% 23% 19% 20% 23% 26% 26% 25%
8 19 69 32 42 57 58 67 84
Interest 11 9 8 9 1 2 4 4 4
Depreciation 36 65 66 71 67 69 77 90 82
Profit before tax 270 365 517 326 355 526 612 576 545
Tax % 20% 18% 19% 24% 21% 22% 23% 15% 17%
217 298 420 249 281 409 473 487 454
EPS in Rs 5.43 7.44 10.49 6.21 7.01 10.22 11.80 12.16 11.34
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
3,918 3,829 4,794 5,523 7,486 8,127 9,265
3,141 3,124 3,550 4,151 5,644 6,429 6,940
Operating Profit 778 705 1,244 1,372 1,842 1,698 2,325
OPM % 20% 18% 26% 25% 25% 21% 25%
209 64 94 154 200 163 267
Interest 18 40 11 8 48 28 15
Depreciation 28 38 62 78 123 270 318
Profit before tax 941 691 1,265 1,440 1,871 1,563 2,260
Tax % 26% 26% 24% 25% 26% 20% 19%
694 514 958 1,084 1,389 1,248 1,823
EPS in Rs 17.33 12.83 23.92 27.07 34.68 31.16 45.52
Dividend Payout % 0% 0% 32% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 19%
3 Years: 19%
TTM: 14%
Compounded Profit Growth
10 Years: %
5 Years: 29%
3 Years: 20%
TTM: 50%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 15%
Return on Equity
10 Years: %
5 Years: 22%
3 Years: 20%
Last Year: 21%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 40 40 40 40 40 40 40
Reserves 2,957 3,025 3,611 4,694 6,500 7,744 9,584
360 190 3 101 688 5 9
652 596 877 1,045 1,710 1,583 1,785
Total Liabilities 4,009 3,851 4,531 5,880 8,939 9,371 11,418
534 778 945 987 2,927 3,142 3,479
CWIP 322 211 148 166 387 495 113
Investments 1,402 1,698 1,784 2,397 2,526 3,102 4,430
1,751 1,164 1,655 2,330 3,100 2,632 3,396
Total Assets 4,009 3,851 4,531 5,880 8,939 9,371 11,418

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
540 537 960 983 821 1,799 1,983
-516 -306 -396 -1,127 -1,360 -1,041 -1,919
8 -240 -559 89 579 -710 -9
Net Cash Flow 31 -9 5 -55 40 48 55

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 23 13 32 24 23 22 30
Inventory Days 120 126 124 169 183 132 135
Days Payable 115 101 113 122 133 103 107
Cash Conversion Cycle 27 38 43 72 73 52 58
Working Capital Days 95 44 41 49 60 40 124
ROCE % 22% 36% 33% 30% 21% 26%

Shareholding Pattern

Numbers in percentages

17 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
76.50% 76.50% 76.50% 74.88% 74.87%
4.18% 4.18% 6.74% 9.87% 11.58%
4.65% 4.56% 9.78% 11.14% 9.94%
14.67% 14.76% 6.97% 4.10% 3.61%
No. of Shareholders 1,31,9181,34,7311,27,4491,35,1161,53,450

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents